博舒替尼诱发的可逆性肺动脉高压：一例报告
Reversible pulmonary arterial hypertension induced by bosutinib: a case report.
作者信息
Ivan Juliette, Esnaud Rose, Orvain Corentin, Khouri Charles, Chaumais Marie-Camille, Humbert Marc, Montani David, Gagnadoux Frédéric
机构信息
Departement of Respiratory and Sleep Medicine, University Hospital of Angers, Angers, France.
Maladies du Sang, CHU Angers, Angers, France.
出版信息
ERJ Open Res. 2025 Jun 2;11(3). doi: 10.1183/23120541.00943-2024. eCollection 2025 May.
Abstract
摘要
https://bit.ly/4fxCggY. （此为链接，无法准确翻译为中文，保留原文即可）
相似文献
1
Reversible pulmonary arterial hypertension induced by bosutinib: a case report.博舒替尼诱发的可逆性肺动脉高压：一例报告
ERJ Open Res. 2025 Jun 2;11(3). doi: 10.1183/23120541.00943-2024. eCollection 2025 May.
2
Successful treatment with nilotinib after bosutinib-induced pulmonary arterial hypertension recurrence following dasatinib in chronic myeloid leukemia in chronic phase.在慢性期慢性髓性白血病中，达沙替尼治疗后博舒替尼诱导的肺动脉高压复发，使用尼罗替尼成功治疗。
Leuk Res Rep. 2022 Apr 19;17:100312. doi: 10.1016/j.lrr.2022.100312. eCollection 2022.
3
Incident pulmonary arterial hypertension associated with Bosutinib.与博舒替尼相关的新发肺动脉高压
Pulm Circ. 2020 Aug 21;10(3):2045894020936913. doi: 10.1177/2045894020936913. eCollection 2020 Jul-Sep.
4
A case of worsening pulmonary arterial hypertension and pleural effusions by bosutinib after prior treatment with dasatinib.一例在先前接受达沙替尼治疗后使用博舒替尼导致肺动脉高压和胸腔积液加重的病例。
Pulm Circ. 2017 Oct-Dec;7(4):808-812. doi: 10.1177/2045893217733444. Epub 2017 Oct 24.
5
Dasatinib-induced pulmonary arterial hypertension - A rare late complication.达沙替尼诱发的肺动脉高压——一种罕见的晚期并发症。
J Oncol Pharm Pract. 2019 Apr;25(3):727-730. doi: 10.1177/1078155217753740. Epub 2018 Jan 17.
6
Dasatinib-induced pulmonary arterial hypertension.达沙替尼致肺动脉高压。
Br J Clin Pharmacol. 2018 May;84(5):835-845. doi: 10.1111/bcp.13508. Epub 2018 Mar 6.
7
Dasatinib-Induced Pulmonary Arterial Hypertension in Chronic Myeloid Leukaemia: A Case Report and Literature Review.达沙替尼诱发慢性髓性白血病患者肺动脉高压：一例报告及文献综述
Respirol Case Rep. 2025 Mar 10;13(3):e70147. doi: 10.1002/rcr2.70147. eCollection 2025 Mar.
8
Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors.Bcr-Abl酪氨酸激酶抑制剂的肺部并发症
Eur Respir J. 2020 Oct 29;56(4). doi: 10.1183/13993003.00279-2020. Print 2020 Oct.
9
Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia.比较博舒替尼、达沙替尼和尼洛替尼二线治疗慢性期慢性髓性白血病的生存和主要细胞遗传学反应的匹配调整间接比较。
Curr Med Res Opin. 2019 Sep;35(9):1615-1622. doi: 10.1080/03007995.2019.1605239. Epub 2019 May 15.
10
Dasatinib-induced pulmonary arterial hypertension complicated with scleroderma: a case report.达沙替尼诱发的肺动脉高压合并硬皮病：一例报告
Eur Heart J Case Rep. 2019 Mar 15;3(1):ytz025. doi: 10.1093/ehjcr/ytz025. eCollection 2019 Mar.
本文引用的文献
1
Definition, classification and diagnosis of pulmonary hypertension.肺动脉高压的定义、分类和诊断。
Eur Respir J. 2024 Oct 31;64(4). doi: 10.1183/13993003.01324-2024. Print 2024 Oct.
2
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.2022年欧洲心脏病学会/欧洲呼吸学会肺动脉高压诊断和治疗指南。
Eur Respir J. 2023 Jan 6;61(1). doi: 10.1183/13993003.00879-2022. Print 2023 Jan.
3
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).2022年欧洲心脏病学会（ESC）与欧洲血液学协会（EHA）、欧洲治疗放射学与肿瘤学协会（ESTRO）以及国际心脏肿瘤学会（IC-OS）合作制定的心脏肿瘤学指南。
Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244.
4
Successful treatment with nilotinib after bosutinib-induced pulmonary arterial hypertension recurrence following dasatinib in chronic myeloid leukemia in chronic phase.在慢性期慢性髓性白血病中，达沙替尼治疗后博舒替尼诱导的肺动脉高压复发，使用尼罗替尼成功治疗。
Leuk Res Rep. 2022 Apr 19;17:100312. doi: 10.1016/j.lrr.2022.100312. eCollection 2022.
5
Pulmonary Arterial Hypertension Worsened by Bosutinib in Patient With Previous Dasatinib Treatment.先前接受达沙替尼治疗的患者使用博舒替尼后肺动脉高压恶化
Am J Ther. 2020 Sep 16;28(6):e704-e706. doi: 10.1097/MJT.0000000000001156.
6
Incident pulmonary arterial hypertension associated with Bosutinib.与博舒替尼相关的新发肺动脉高压
Pulm Circ. 2020 Aug 21;10(3):2045894020936913. doi: 10.1177/2045894020936913. eCollection 2020 Jul-Sep.
7
Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors.Bcr-Abl酪氨酸激酶抑制剂的肺部并发症
Eur Respir J. 2020 Oct 29;56(4). doi: 10.1183/13993003.00279-2020. Print 2020 Oct.
8
Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study.与蛋白激酶抑制剂相关的肺动脉高压：一项药物警戒-药效学研究。
Eur Respir J. 2019 May 9;53(5). doi: 10.1183/13993003.02472-2018. Print 2019 May.
9
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.博舒替尼对比伊马替尼用于新诊断的慢性髓性白血病：随机 BFORE 试验结果。
J Clin Oncol. 2018 Jan 20;36(3):231-237. doi: 10.1200/JCO.2017.74.7162. Epub 2017 Nov 1.
10
A case of worsening pulmonary arterial hypertension and pleural effusions by bosutinib after prior treatment with dasatinib.一例在先前接受达沙替尼治疗后使用博舒替尼导致肺动脉高压和胸腔积液加重的病例。
Pulm Circ. 2017 Oct-Dec;7(4):808-812. doi: 10.1177/2045893217733444. Epub 2017 Oct 24.
Zotero 插件